Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene therapy for collateral vessel development

G Melillo1, M Scoccianti, I Kovesdi

  • 1Laboratorio di Patologia Vascolare, Istituto Dermopatico dell'Immacolata, Rome, Italy.

Cardiovascular Research
|January 31, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

miR-200c inhibition and catalase accelerate diabetic wound healing.

Journal of biomedical science·2025
Same author

The Oxidative Stress-Induced miR-200c Is Upregulated in Psoriasis and Correlates with Disease Severity and Determinants of Cardiovascular Risk.

Oxidative medicine and cellular longevity·2020
Same author

Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database.

The British journal of dermatology·2018
Same author

No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasis.

The British journal of dermatology·2017
Same author

Cardiac mesenchymal stromal cells are a source of adipocytes in arrhythmogenic cardiomyopathy.

European heart journal·2015
Same author

Vascular Imaging: Overview Where Is This Technology Leading? What's the Best Bet for the Future?

Surgical technology international·2015
Same journal

Metabolic crisis and TRPM4 activation cause QT prolongation in TANGO2 deficiency disorder.

Cardiovascular research·2026
Same journal

Personalizing Atrial Fibrillation Therapy: Moving from Genetic Association to Mechanistic Translation.

Cardiovascular research·2026
Same journal

Placental Growth Factor Promotes Endothelial Activation and Inflammatory Remodelling in Pulmonary Hypertension.

Cardiovascular research·2026
Same journal

Endothelial-to-mesenchymal transition (EndMT) in atherosclerosis: mechanisms, models and therapies.

Cardiovascular research·2026
Same journal

The gut-heart axis in cardio-oncology.

Cardiovascular research·2026
Same journal

Proteomic signatures as biomarkers of atherosclerosis burden.

Cardiovascular research·2026
See all related articles

Gene transfer of cDNA for angiogenic factors offers a promising method to promote therapeutic angiogenesis and improve blood flow in ischemic tissues. Further research is needed for routine clinical application of this gene therapy.

Area of Science:

  • Molecular Biology
  • Cardiovascular Research
  • Regenerative Medicine

Background:

  • Ischemic conditions like myocardial and limb ischemia lack effective revascularization options.
  • Therapeutic angiogenesis aims to stimulate new blood vessel formation.
  • Gene transfer of angiogenic factors is an emerging strategy.

Purpose of the Study:

  • To review gene transfer techniques for therapeutic angiogenesis in myocardial and limb ischemia.
  • To summarize experimental evidence of angiogenic factors in animal and human studies.
  • To identify key questions for clinical gene therapy application.

Main Methods:

  • Review of experimental studies on recombinant growth factors and gene transfer methods.
  • Analysis of animal models and human trials demonstrating angiogenic effects.

Related Experiment Videos

  • Literature search for gene transfer studies focused on therapeutic angiogenesis.

    • Main Results:

    • Experimental studies show the angiogenic potential of recombinant growth factors.
    • Various gene transfer methods have been explored for delivering angiogenic factors.
    • Evidence supports the feasibility of inducing therapeutic angiogenesis via gene transfer.

    Conclusions:

    • Gene transfer of angiogenic factors holds significant promise for treating ischemic diseases.
    • Critical questions remain regarding safety and efficacy for routine clinical use.
    • Further research is essential to translate gene therapy with angiogenic factors into clinical practice.